Back to Neurology
Neurologyv1999Evidence-Based

Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale

Assesses disease severity and functional status in patients with myasthenia gravis by evaluating 8 activities of daily living commonly affected by MG symptoms. This patient-reported scale measures symptom impact on bulbar, respiratory, gross motor, and ocular functions.

Clinical Input Parameters

Clinical Assessment
Awaiting Parameters
mg adl score
—points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Myasthenia Gravis Activities of Daily Living (MG-ADL) Scale is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within neurology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

MG-ADL Total Score = Talking + Chewing + Swallowing + Breathing + Brushing teeth/combing hair + Rising from chair + Eyelid droop + Double vision (each item scored 0-3)

Clinical Pearls & Practice Notes

  • The MG-ADL scale is an 8-item patient-reported outcome measure specifically designed for myasthenia gravis
  • Each item is scored from 0 (normal) to 3 (most severe), giving a total possible score of 0-24
  • A 2-point reduction in total score represents clinically meaningful improvement
  • The scale evaluates bulbar functions (talking, chewing, swallowing), respiratory function, gross motor function, and ocular symptoms
  • Administered based on patient recall of symptoms during the prior week
  • Easy to use, requires no special training, and can be completed in under 10 minutes
  • Correlates well with other MG severity measures including QMG score and MG Composite
  • Widely used in clinical trials and routine clinical practice for monitoring disease severity and treatment response
  • Each individual item score may be clinically significant even when total score appears low

Evidence & Literature Citations

  1. Wolfe GI, Herbelin L, Nations SP, Foster B, Bryan WW, Barohn RJ. Myasthenia gravis activities of daily living profile. Neurology. 1999;52(7):1487-9. doi: 10.1212/wnl.52.7.1487.
  2. Muppidi S, Wolfe GI, Conaway M, Burns TM; MG Composite and MG-QOL15 Study Group. MG-ADL: still a relevant outcome measure. Muscle Nerve. 2011;44(5):727-31. doi: 10.1002/mus.22140.
  3. Burns TM, Conaway M, Sanders DB; MG Composite and MG-QOL15 Study Group. The MG Composite: A valid and reliable outcome measure for myasthenia gravis. Neurology. 2010;74(18):1434-40. doi: 10.1212/WNL.0b013e3181dc1b1e.

Score Interpretation Ranges

Minimal0 – 2 pts

Minimal functional impairment

Mild3 – 6 pts

Mild functional impairment

Moderate7 – 12 pts

Moderate functional impairment

Severe13 – 18 pts

Severe functional impairment

Very Severe19 – 24 pts

Very severe functional impairment

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.